BioMarin Pharmaceutical Inc. 105 Digital Drive Novato,
CA 94949 United States - Map Phone: 415-506-6700 Fax: 415-382-7889 Website: http://www.biomarinpharm.com
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The companys commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California. Key Statistics
| |
| BioMarin Pharmaceutical Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (High Concern), Shareholder Rights (Medium Concern). | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Jean-Jacques Bienaim ,
58 Chief Exec. Officer and Director | 1.56M | 309.00K | Mr. Stephen Aselage ,
60 Chief Bus. Officer and Exec. VP | 556.00K | 929.00K | Dr. Henry J. Fuchs M.D., Ph.D.,
54 Chief Medical Officer and Exec. VP | 616.00K | 338.00K | Dr. Robert A. Baffi Ph.D.,
57 Exec. VP of Technical Operations | 488.00K | 456.00K | Mr. Daniel K. Spiegelman M.B.A.,
53 Chief Financial Officer and Exec. VP | N/A | N/A |
|
| | Amounts are as of Dec 30, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|